4-氯-2,6-双(二甲基氨基)嘧啶 | 1202-22-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-氯-2,6-双(二甲基氨基)嘧啶
• 英文名称: 4-Chlor-2,6-bis-dimethylamino-pyrimidin
• 英文别名: 6-chloro-N2,N2,N4,N4-tetrapyrimidin-2,4-diamine；6-chloro-N²,N²,N⁴,N⁴-tetramethyl-pyrimidine-2,4-diamine；6-chloro-N²,N²,N⁴,N⁴-tetramethyl-pyrimidine-2,4-diyldiamine；6-Chlor-N²,N²,N⁴,N⁴-tetramethyl-pyrimidin-2,4-diyldiamin；6-chloro-N,N,N',N'-tetramethyl-pyrimidine-2,4-diamine；2,4-bis[dimethylamino]-6-chloropyrimidine；4-Chloro-2,6-bis(dimethylamino)pyrimidine；6-chloro-2-N,2-N,4-N,4-N-tetramethylpyrimidine-2,4-diamine
• CAS: 1202-22-8
• 化学式: C₈H₁₃ClN₄
• mdl: MFCD01873147
• 分子量: 200.671
• InChiKey: WOYUZQVWDISJCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-氯-2,6-双(二甲基氨基)嘧啶 在 盐酸 、 potassium carbonate 、 sodium nitrite 作用下， 以 水 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  通过基于结构的虚拟筛选和合理的先导优化发现偶氮氨基嘧啶作为 Chi-h 抑制剂的新型有效几丁质酶

  摘要：

  来自破坏性农业害虫 Ostrinia furnacalis 的 Chi-h几丁质酶被认为是绿色害虫控制和管理的有希望的目标。在这项研究中，基于结构的虚拟筛选和合理的分子优化导致合成了一系列偶氮氨基嘧啶衍生物作为一类新型的 O f Chi-h 抑制剂。其中，最有效的化合物8f，在嘧啶4位的氨基上有一个苄基，对O f Chi-h的K i值为64.7 nM 。此外，进行分子对接研究以研究氨基嘧啶对 O f效力的基础智H。此外，还评估了目标化合物对小菜蛾和Ostrinia nubilalis的杀虫活性，有效的 O f Chi-h 抑制剂8f和8i显示出比对照农药六氟嘧啶更高的杀虫活性。目前的工作表明，具有化学结构简洁和高效的偶氮氨基嘧啶骨架可以进一步开发为防治鳞翅目害虫的潜在农药。

  DOI：

  10.1021/acs.jafc.2c03997
• 作为产物：
  描述：

  4,6-二氯-N,N-二甲基-2-氨基嘧啶 、 二甲胺 在 乙醇 作用下， 生成 4-氯-2,6-双(二甲基氨基)嘧啶
  参考文献：
  名称：

  Nutritional Parameters, Body Composition, and Progression of Disability in Older Disabled Residents Living in Nursing Homes

  摘要：

  Background. The evaluation of nutritional status is one of the primary components of multidimensional geriatric assessment. We investigated the relationship between some markers of malnutrition and the modification,ns in functional status in a sample of older disabled residents living in nursing homes.Methods. Ninety-eight subjects who were independent in at least two activities of daily living (ADLs) were enrolled in a 2-year longitudinal study. Anthropometric. nutritional, and metabolic parameters. as well us body composition. were measured at baseline and after 2 years.Results. Deteriorating functional status (greater than or equal to2 additional lost ADLs) was associated with baseline albumin levels (Tertile 3 vs Tertile 1: odds ratio [OR] 0.16, 95% confidence interval [CI] 0.01-0.67) and subscapular skinfold thick,less (Tertile 3 vs Tertile 1:OR 0.06, 95% CI 0.006-0.50). After multivariate adjustment. the OR for increasing disability was >4 in subjects with decreasing body cell mass (BCM), compared with subjects with a stable BCM. The degree of BCM reduction was strongly related to the number of additional ADLs lost at follow-up (test for trend. p = .003).Conclusions. In a sample of older disabled nursing home residents, signs of malnutrition seem to predict further worsening in functional status. Furthermore. BCM declines proportionally to the loss in ADLs. suggesting the existence of a strong relationship between BCM loss and the progressive deterioration of functional status.

  DOI：

  10.1093/gerona/56.4.m212

文献信息

• TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE
  申请人：Prevost Grégorie

  公开号：US20100137275A1

  公开（公告）日：2010-06-03

  The present invention relates to the novel triaminopyrimidine derivatives of formula (I) in which R1, R2, W, R3, R4, and R5 are variable groups. These products have a Cdc25-phosphatase-inhibiting activity. The invention also relates to a process for synthesizing these compounds and also to therapeutic compositions containing these products and to the use thereof as medicaments.

  本发明涉及公式（I）中的新型三氨基嘧啶衍生物，其中R1、R2、W、R3、R4和R5为可变基团。这些产物具有Cdc25磷酸酶抑制活性。该发明还涉及合成这些化合物的方法，以及含有这些产物的治疗组合物，以及将其用作药物的用途。
• Isotopic Exchange of Hydrogen at C-5 in Pyrimidine Derivatives: Tautomers with an sp³-Hybridised C-5 Carbon Atom
  作者：Martin Dračínský、Antonín Holý、Petr Jansa、Soňa Kovačková、Miloš Buděšínský

  DOI：10.1002/ejoc.200900529

  日期：2009.8

  The proton-to-deuterium exchange reaction of the hydrogen atom at the 5-position of 15 pyrimidine derivatives has been studied. The exchange proceeds under both acidic and alkaline conditions. Under acidic conditions, the mechanism involves protonation at the 5-position (forming an σ complex), whereas under alkaline conditions the exchange is mainly a result of the formation of a tautomeric equilibrium

  研究了15种嘧啶衍生物5位氢原子的质子-氘交换反应。交换在酸性和碱性条件下进行。在酸性条件下，该机制涉及在 5 位进行质子化（形成 σ 复合物），而在碱性条件下，交换主要是形成互变异构平衡的结果，其中一个互变异构体在第5 位。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• [EN] C20 THROUGH C26 AMINO STEROIDS
  申请人：THE UPJOHN COMPANY

  公开号：WO1987001706A2

  公开（公告）日：1987-03-26

  (EN) Disclosed are $g(D)9(11)-steroids (VI) and amino substituted steroids of formula (XI), which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), $g(D)16-steroids (IIIa and IIIb), reduced A-ring steroids (IV), $g(D)17(20)-steroids (Va and Vb) and $g(D)9(11)-steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.(FR) Stéroïdes $g(D)9(11) (VI) et stéroïdes à substitution amino de formule (XI), contenant un groupe amino fixé à la terminaison d'atome de carbone de la chaîne côté C17, plus particulièrement amino-stéroïdes (Ia et Ib), stéroïdes aromatiques (II), stéroïdes $g(D)16 IIIa et IIIb), stéroïdes à composés cycliques A réduits (IV), stéroïdes $g(D)17(20) (Va et Vb) et stéroïdes $g(D)9(11) (VI) utiles en tant qu'agents pharmaceutiques pour traiter un certain nombre d'états.

  揭示了$g(D)9(11)-类固醇(VI)和式子(XI)的氨基取代类固醇，其中包含连接到C17侧链末端碳原子的氨基基团，更具体地包括氨基类固醇(Ia和Ib)，芳香族类固醇(II)，$g(D)16-类固醇(IIIa和IIIb)，还原A环类固醇(IV)，$g(D)17(20)-类固醇(Va和Vb)和$g(D)9(11)-类固醇(VI)，这些类固醇可用作治疗多种疾病的药物。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF
  申请人：Sekiguchi Yoshinori

  公开号：US20090036448A1

  公开（公告）日：2009-02-05

  The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了新型取代嘧啶化合物的公式（I）：这些化合物作为MCH受体拮抗剂。这些化合物在制药组合物中的用途包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症（包括贪食症和厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。